KGET: AI 评分 57/100 — AI 分析 (4月 2026)

CaliPharms, Inc. is a US-based company focused on the medicinal cannabis industry, specifically THC and CBD beverages. Formerly known as Kleangas Energy Technologies, it rebranded in 2017 to concentrate on cannabis-related ventures.

Key Facts: AI Score: 57/100 Sector: Basic Materials

公司概况

概要：

CaliPharms, Inc. operates within the evolving medicinal cannabis sector, concentrating on THC and CBD-infused beverages. The company, formerly Kleangas Energy Technologies, shifted its focus in 2017. It faces competition in a dynamic market while striving to establish its brand in the cannabis beverage segment.

KGET是做什么的？

CaliPharms, Inc., headquartered in Temecula, California, is a participant in the United States' medicinal cannabis industry. The company's primary focus is the development and potential distribution of beverages infused with THC and CBD. CaliPharms, Inc. was originally established under the name Kleangas Energy Technologies, Inc., reflecting an earlier business direction. In January 2017, the company underwent a strategic shift, rebranding itself as CaliPharms, Inc. to align with its new focus on the cannabis market. This transition marked a significant change in business strategy, moving away from energy technologies to capitalize on the emerging opportunities within the medicinal cannabis sector. The company is positioning itself to cater to the growing demand for cannabis-infused products, particularly in the beverage segment. CaliPharms, Inc. is working to establish its presence in a competitive market, navigating the regulatory landscape and consumer preferences within the cannabis industry.

KGET的投资论点是什么？

CaliPharms, Inc. presents a high-risk, high-reward investment profile due to its early-stage involvement in the cannabis-infused beverage market. The company's success hinges on its ability to navigate complex regulatory hurdles and establish a strong brand presence. Key value drivers include successful product development, effective marketing, and strategic partnerships. The company's negative P/E ratio of -0.01 and a profit margin of -11861.4% indicate significant financial challenges. Investors should closely monitor the company's cash flow, debt levels, and ability to secure funding for future growth. The high beta of -58.74 suggests extreme volatility relative to the market.

KGET在哪个行业运营？

CaliPharms, Inc. operates in the rapidly evolving cannabis industry, specifically targeting the infused beverage market. This sector is characterized by changing regulations, increasing competition, and growing consumer acceptance. The market is driven by the increasing legalization of cannabis for medicinal and recreational purposes in various states. CaliPharms faces competition from established players in the beverage industry and emerging cannabis companies. The company's success depends on its ability to differentiate its products and navigate the complex regulatory landscape.

Agricultural Inputs

Basic Materials

KGET有哪些增长机遇？

Expansion into New Markets: As cannabis legalization expands across the United States, CaliPharms, Inc. has the opportunity to enter new markets. Each new state represents a potential revenue stream, provided the company can navigate the local regulatory environment. The timeline for this growth is dependent on the pace of legalization efforts and the company's ability to secure licenses and distribution agreements. The market size for cannabis beverages is projected to reach billions of dollars in the coming years.
Product Diversification: CaliPharms, Inc. can expand its product line beyond THC and CBD beverages to include other cannabis-infused products, such as edibles, topicals, and concentrates. This diversification would allow the company to cater to a wider range of consumer preferences and increase its market share. The timeline for product diversification depends on the company's R&D capabilities and its ability to obtain regulatory approval for new products. The market for cannabis-infused products is diverse and growing rapidly.
Strategic Partnerships: Forming strategic partnerships with established beverage distributors or cannabis retailers can provide CaliPharms, Inc. with access to wider distribution networks and increased brand visibility. These partnerships can accelerate the company's growth and reduce its reliance on direct sales. The timeline for establishing strategic partnerships depends on the company's networking efforts and its ability to negotiate favorable terms. The benefits of strategic partnerships can be significant, including increased revenue and market share.
Branding and Marketing: Investing in branding and marketing efforts can help CaliPharms, Inc. establish a strong brand identity and differentiate itself from competitors. Effective marketing campaigns can increase consumer awareness and drive sales. The timeline for building a strong brand depends on the company's marketing budget and its ability to create compelling messaging. A strong brand can command premium pricing and increase customer loyalty.
Research and Development: Investing in research and development can enable CaliPharms, Inc. to develop innovative new products and improve the quality and efficacy of its existing products. This can give the company a competitive advantage and attract new customers. The timeline for R&D depends on the company's resources and its ability to conduct successful clinical trials. Successful R&D can lead to patentable products and increased market share.

Market capitalization of $0.00B indicates a micro-cap company with limited resources and higher risk.
Negative P/E ratio of -0.01 reflects the company's current lack of profitability.
Profit Margin of -11861.4% highlights significant operational inefficiencies and challenges in achieving profitability.
Gross Margin of 100.0% suggests high potential profitability if operational costs are managed effectively.
Beta of -58.74 indicates an extremely volatile stock, moving inversely to the market.

KGET提供哪些产品和服务？

Engages in the medicinal cannabis industry in the United States.
Focuses on the development of THC and CBD beverages.
Aims to capitalize on the growing market for cannabis-infused products.
Navigates the regulatory landscape of the cannabis industry.
Seeks to establish a brand presence in the cannabis beverage segment.
Works to develop and distribute cannabis-infused beverages.

KGET如何赚钱？

Develops and potentially distributes THC and CBD-infused beverages.
Aims to generate revenue through the sale of these beverages.
Focuses on the medicinal cannabis market in the United States.

Consumers seeking medicinal cannabis products.
Individuals interested in THC and CBD-infused beverages.
Patients with medical conditions that may benefit from cannabis use.

First-mover advantage in specific regional markets.
Proprietary formulations for THC and CBD beverages.
Established relationships with cannabis cultivators and distributors.

什么因素可能推动KGET股价上涨？

Upcoming: Potential changes in cannabis regulations at the state or federal level could create new market opportunities.
Ongoing: Increasing consumer acceptance of cannabis-infused beverages could drive demand and revenue growth.
Ongoing: Development and launch of new cannabis-infused beverage products could attract new customers.
Upcoming: Securing partnerships with established beverage distributors could expand market reach.
Ongoing: Positive clinical trial results for cannabis-based therapies could increase investor confidence.

KGET的主要风险是什么？

Potential: Stringent regulations and licensing requirements could limit market access.
Ongoing: Intense competition from larger cannabis companies could erode market share.
Potential: Negative public perception of cannabis could hinder demand growth.
Ongoing: Limited access to capital and funding could constrain growth plans.
Potential: Product recalls or safety concerns could damage brand reputation.

KGET的核心优势是什么？

Focus on the growing cannabis beverage market.
Potential for first-mover advantage in specific regions.
Experienced management team with knowledge of the cannabis industry.

KGET的劣势是什么？

Limited financial resources compared to larger competitors.
Dependence on regulatory approvals for growth.
Lack of established brand recognition.

KGET有哪些机遇？

Expansion into new markets as cannabis legalization progresses.
Development of innovative cannabis-infused products.
Strategic partnerships with established beverage distributors.

KGET面临哪些威胁？

Increasing competition from larger cannabis companies.
Changing regulations and potential for stricter enforcement.
Negative public perception of cannabis.

KGET的竞争对手是谁？

Canopy Growth Corporation — Large-scale cannabis producer with a wide range of products. — (CPYCF)
Green Thumb Industries Inc. — Vertically integrated cannabis operator with a strong retail presence. — (GTCP)
MedMen Enterprises Inc. — Cannabis retailer with a focus on premium products and customer experience. — (MTMW)
Nass Valley Gateway Ltd. — Focuses on the sales and distribution of hemp-based CBD products. — (NSAUF)
Planet 13 Holdings Inc. — Operates a large cannabis entertainment complex in Las Vegas. — (PNLT)

Key Metrics

MoonshotScore: 57/100

Company Profile

CEO: Eric Watson
Headquarters: Temecula, US
Founded: 2013

AI Insight

AI analysis pending for KGET

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does CaliPharms, Inc. do?

CaliPharms, Inc. is a company operating within the medicinal cannabis industry in the United States. Its primary focus is on the development and potential distribution of beverages infused with THC and CBD. The company aims to capitalize on the growing demand for cannabis-infused products, particularly in the beverage segment, by creating and marketing these specialized drinks. CaliPharms, Inc. is positioning itself to cater to consumers seeking alternative methods of cannabis consumption.

What do analysts say about KGET stock?

There is no available analyst coverage for KGET stock. The company's micro-cap status and OTC listing may contribute to the lack of analyst attention. Investors should conduct their own thorough research and due diligence before investing in KGET, considering the limited information and potential risks associated with the stock. Key valuation metrics to consider include revenue growth, gross margin, and cash flow.

What are the main risks for KGET?

KGET faces several risks inherent to its position as a small company in the cannabis industry. These include intense competition from larger, better-funded companies, the evolving and uncertain regulatory landscape surrounding cannabis, and potential challenges in securing financing for growth. The company's reliance on the cannabis beverage market also exposes it to risks related to changing consumer preferences and potential product recalls. Additionally, as an OTC-listed stock, KGET carries liquidity and disclosure risks.